Recipharm Signs Agreement to Manufacture Liproca Depot
PTSM: Pharmaceutical Technology Sourcing and Management
Recipharm has signed an agreement with Sweddish pharmaceutical company LIDDS for the production scale up and manufacture of LIDDS’ Liproca depot for the treatment of prostate cancer.
Recipharm announced that it has signed an agreement with Swedish pharmaceutical company LIDDS for the production scale up and manufacture of LIDDS’ Liproca depot for the treatment of prostate cancer.
The patented technology, Liproca depot, is a novel bioresorbable, biocompatible, and locally injectable modified-release formulation of 2-hydroxyflutamid, prepared as a paste, prior to injection, and which cures shortly after injection. The product is delivered in a prefilled syringe, which also serves as mixing equipment of the paste prior to injection.
This agreement marks an important step in the preparation of a Phase IIb study of Liproca depot, which is expected to begin in 2016. In connection with the agreement, Recipharm has invested SEK 5 million in a private placement, making it the third largest shareholder of LIDDS.
Source: Recipharm
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.
